Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Optical purity evaluation and accelerated aging of the new Clareon biomaterial vs other hydrophobic acrylic material in a laboratory setup

Search Title by author or title

Session Details

Session Title: Cataract Surgery Complications: IOL Dislocation and Opacification

Session Date/Time: Tuesday 10/10/2017 | 14:00-16:00

Paper Time: 15:42

Venue: Room 3.6

First Author: : G.Auffarth GERMANY

Co Author(s): :    S. Schickhardt   Q. Wang   H. Fang   F. Hengerer           

Abstract Details

Purpose:

The objective was to determine in an vitro study optical purity of the Intraocular Lens (IOL) material of the Alcon Clareon SY60WF and comparative IOLs (AMO Tecnis PCB00, Bausch & Lomb Envista and Hoya Vivinex XC1) regarding the development of glistenings.

Setting:

David J. Apple International Laboratory for Ocular Pathology, Department of Ophthalmology, University of Heidelberg, Germany

Methods:

The lenses were immersed in a NaCl solution (0,9%) and incubated at 45° for 24 hours in an oven. Afterwards the temperature was reduced to 37° using a water bath. The lenses were stored at 37° for 2.5 hours. After that the lenses were analyzed under a microscope and a dedicated image analysis software was used to count and evaluate glistening formation in the lens material.

Results:

Glistenings formation was quantified in numbers of microvacuoles/mm² (MV/mm²). The glistening formation in the lenses were for the Bausch & Lomb Envista 1.5 ± 0.9 MV/mm², Clareon 4.09 ± 6.67 MV/mm², AMO Tecnis 4.47 ± 5.92 MV/mm² and Hoya Vivinex XC1 6.07 ± 16.72 MV/mm².

Conclusions:

On the so called Miyata scale for clinical glistening grading all lenses were on scale of zero, meaning less then 25 MV/mm². The Clareon SY60WF material can be considered as a glistening free as the Envista IOL from Bausch & Lomb.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a competing company, research is funded, fully or partially, by a competing company, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives nonNONEmonetary benefits from a competing company., receives nonNONEmonetary benefits from a company producing, developing or supplying the product or procedure presented., receives consulting fees, retainer, or contract payments from a competing company

Back to previous